Company intelligence / Profile preview

GramEye

Ibaraki, Osaka Prefecture, Japangrameye.com ↗

Ownership: Private
Development stage: Preclinical

Overview

GramEye is developing an automated medical device that uses artificial intelligence to rapidly identify and analyze drug-resistant bacteria, aiming to support appropriate antibiotic prescription and combat antimicrobial resistance. The company is a spin-out from Osaka University and is currently focused on product development rather than clinical trials[4].

Therapeutic areas: OtherInfectious Diseases
Modalities: DeviceArtificial intelligence-based diagnostics
Industry: Digital Health Medical Devices

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on GramEye.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GramEye.

Explore the full profile